NeuroMetrix Signs DPNCheck® Collaboration Agreement with Biomedix
26 June 2020 - 3:00AM
NeuroMetrix, Inc. (Nasdaq: NURO) today reported that it has signed
a collaboration agreement with Biomedix to comarket DPNCheck for
peripheral neuropathy detection within Medicare Advantage and other
value-based care markets. NeuroMetrix and Biomedix provide
complementary diagnostic tests to physicians and health plans.
Within these markets, healthcare providers are focused on detecting
and documenting chronic health conditions to determine risk and
prevent their costly and debilitating complications.
Biomedix will integrate DPNCheck sural nerve conduction data
into the Biomedix Xchange population health platform. This will
simplify the documentation process for health plans by combining
results from multiple diagnostic tests into one data exchange file
for the electronic medical record system.
“We are pleased to partner with Biomedix,” said Shai N. Gozani,
M.D., Ph.D., President and CEO of NeuroMetrix, Inc. “Having
Biomedix comarket DPNCheck will provide valuable exposure within
Medicare Advantage and potentially other value-based care
organizations. The integration of DPNCheck data into the Biomedix
Xchange platform will give customers a streamlined approach to
documenting diagnostic results performed during health risk
assessments.”
“The NeuroMetrix partnership represents a strategic milestone in
our effort to improve the delivery of cost-effective care to
patients in clinics as well as in homes,” said John Romans, CEO of
Biomedix. “Integrating DPNCheck into our HITRUST-certified platform
broadens our ability to identify, treat, and manage conditions such
as peripheral neuropathy and peripheral artery disease (PAD); two
chronic disease states that are highly prevalent in Medicare
populations.”
About Biomedix
Biomedix is a provider of front-line diagnostic solutions for
delivering value-based care. Biomedix Xchange is a population
health solution that centralizes data for analyzing population
health across multiple chronic conditions. For more information,
visit Biomedix.com.
About PADnet & PADnet Xpress Biomedix is
the maker of PADnet, the market leader in front-line diagnostics
for peripheral vascular disease. PADnet is the only diagnostic
device that can support the identification of PAD and chronic
venous insufficiency (CVI) through a unique collaborative care
model. PADnet Xpress represents the latest technology for quick and
accurate PAD detection, custom-designed for value-based care,
including Medicare Advantage Organizations (MAOs).
About DPNCheck
DPNCheck is a fast, accurate, and quantitative nerve conduction
test that is used to evaluate peripheral neuropathies, such as
diabetic peripheral neuropathy (DPN). It is designed to be used by
clinicians at the point-of-care to objectively detect, stage, and
monitor peripheral neuropathies. For more information, please
visit DPNCheck.com.
About NeuroMetrix
NeuroMetrix is a leading developer and manufacturer of
diagnostic and therapeutic neurostimulation-based medical devices
that are used throughout the world. The Company has
three FDA cleared commercial products. DPNCheck® is
a point-of-care test that is used to evaluate peripheral
neuropathies. ADVANCE™ is a point-of-care device that
provides nerve conduction studies as an aid in diagnosing and
evaluating patients suspected of having focal or systemic
neuropathies. Quell® 2.0 is a wearable, mobile app
enabled, neurostimulation device indicated for symptomatic relief
and management of chronic pain and is available OTC. For more
information, visit NeuroMetrix.com.
NeuroMetrix, Inc. Thomas T. Higgins, 781-314-2761 SVP and Chief
Financial Officer neurometrix.ir@neurometrix.com
Source: NeuroMetrix, Inc.
NeuroMetrix (NASDAQ:NURO)
Historical Stock Chart
From Apr 2024 to May 2024
NeuroMetrix (NASDAQ:NURO)
Historical Stock Chart
From May 2023 to May 2024